Piqray:
Vijoice:
Contraindicated in:
Use Cautiously in:
CV: peripheral edema.
Derm: Stevens-johnson syndrome (SJS), alopecia, drug reaction with eosinophilia and systemic symptoms (dress), dry skin, erythema Multiform (EM), pruritus, rash, toxic epidermal necrolysis (TEN), cellulitis, eczema.
Endo: hyperglycemia, hypoglycemia, hyperglycemic hyperosmolar non-ketotic syndrome, KETOACIDOSIS.
F and E: hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia.
GI: ↓ appetite, ↑ lipase, ↑ liver enzymes, abdominal pain, diarrhea, hyperbilirubinemia, metallic taste, nausea, stomatitis, vomiting, colitis.
GU: ↑ serum creatinine, ↓ fertility, acute kidney injury.
Hemat: anemia, lymphocytopenia, thrombocytopenia.
Metab: ↓ weight, hypercholesterolemia, hypertriglyceridemia, hypoalbuminemia.
Neuro: fatigue, headache, insomnia.
Resp: cough, PNEUMONITIS.
Misc: fever, infection, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Breast Cancer
PIK3CA-Related Overgrowth Spectrum
Absorption: Well absorbed following oral administration.
Distribution: Widely distributed to tissues.
Metabolism/Excretion: Primarily metabolized via hydrolysis; also metabolized to a lesser extent by CYP3A4. Excreted in feces (36% as unchanged drug; 32% as metabolites) and urine (2% as unchanged drug; 7% as metabolites).
Half-life: 89 hr.
NDC Code*